Genespire is an Italian biotech company created by Fondazione Telethon and Ospedale San Raffaele which develops innovative lentiviral gene therapies for the treatment of rare diseases.

Genespire is developing off-the-shelf gene therapies based on immune shielded lentiviral vectors (ISLVs) for pediatric patients affected by genetic diseases. ISLVs are designed to be used intravenously and allow the life-long production of the therapy directly from the patient’s liver. Genespire is initially advancing therapeutic programs in inherited metabolic diseases with high unmet medical need.

Genespire raised €46.6 million (~$52 million) in a Series B round one of the largest private Italian Biotech company financings to date.

Genespire entered in Indaco Bio portfolio in 2024.